Werner Lubitz holds an MSc and a PhD in Microbiology from the Technical University of Munich, Germany. He obtained his postdoctoral training in Cell- and Tumor-Biology at the Institute of Cell Biology, University of Munich, Germany, at the Centre Hopitalier Universitaire Vaudois (CHUV) Lausanne, Switzerland, at the Wallenberg Laboratories, University of Uppsala, Sweden, at the Biocenter, University of Basel, Switzerland, and at the Max Plank Institute of Neurobiology, Martinsried, Germany, and in Genetic Engineering and Microbiology at the Institute of Microbiology, University of Victoria, Canada. Werner Lubitz was Associate Professor of Microbiology at the Institute of Microbiology, University of Kaiserslautern, Germany, and Associate Professor of Genetic at the Institute of Genetic, University of Munich, Germany. Since 1987, he was Full Professor of Microbiology and Biotechnology at the University of Vienna, Austria, first at the Department of Microbiology, Genetics and Immunology, later at the Department of Medicinal Chemistry, and the Center of Molecular Biology, Vienna Biocenter. He is the inventor of the Bacterial Ghost Platform Technology (BGPT) and holds an extensive patent portfolio. Werner is the founder and cofounder of three Biotech Companies including BIRD-C holding the position of CEO/CSO of the latter company exploring different application areas of the BGPT.